Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.
InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.